US Congress · 119th Congress (2025-2026)

HR 8205Passed Origin Chamber

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Source of recordUS Congress · congress.govLast synced Aug 21, 2026

Chamber

House

Progress

Where this bill stands in the legislative process.

Introduced
Passed House
Passed Senate
To President
Became Law

Overview

This bill reauthorizes the Accelerating Access to Critical Therapies for ALS Act through 2031, extending its support for research and access to treatments for Amyotrophic Lateral Sclerosis (ALS). It includes changes to improve the grant review process by requiring a review of clinical trial status and encouraging manufacturers to share interim data. The bill also directs the Food and Drug Administration to publish a report on its action plans for rare neurodegenerative diseases, including an update to the existing 2022 plan and an assessment of its impact.

Key provisions

Extends the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031.
Requires a review of clinical trial status when evaluating grant renewal applications for ALS therapies.
Mandates manufacturers to share interim clinical trial data with the FDA.
Clarifies the definition of ‘phase 3’ clinical trials to include combined phase 2/3 trials and planned phase 3 trials.
Directs the FDA to publish a report on its action plans for rare neurodegenerative diseases, updating the 2022 plan.
Requires the FDA report to assess the impact of the 2022 Action Plan and other initiatives.
Instructs the GAO to submit a report analyzing data related to ALS research and treatment access.

Who is affected

People with ALS and their families
Researchers developing ALS therapies
The Food and Drug Administration

Bill text

Read the latest version inline or switch to a previous version.

Apr 6, 2026XMLView source

Text extraction is in progress. View the official source.

Legislative history

20 recorded actions · showing the most recent 12

Jul 9, 2026House

Placed on the Union Calendar, Calendar No. 637.

Jul 9, 2026House

Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

Jul 9, 2026

Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

Jul 20, 2026House

At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.

Jul 20, 2026House

DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.

Jul 20, 2026House

Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)

Jul 20, 2026House

Mr. Guthrie moved to suspend the rules and pass the bill, as amended.

Jul 22, 2026House

Motion to reconsider laid on the table Agreed to without objection.

Jul 22, 2026House

On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

Jul 22, 2026

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

Jul 22, 2026House

Considered as unfinished business. (consideration: CR H5159)

Jul 23, 2026Senate

Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.

Votes

Recorded roll calls and chamber actions on this bill.

Passage without roll call

The official record shows passage by unanimous consent or voice vote where no roll call was taken. No member-level tally is available for these steps, and the district map does not apply.

7/22/2026HouseVoice vote
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
No roll-call vote on record for this action.
7/22/2026Voice vote
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
No roll-call vote on record for this action.

Floor votes and chamber actions

Recorded roll calls list how each member voted. Unanimous consent or voice vote appears in the official action history without a roll call; no member-level tally is available for those steps.

Passage without roll call

Jul 22, 2026HouseVoice vote
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
No roll-call vote on record for this action.
Jul 22, 2026Voice vote
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
No roll-call vote on record for this action.

Geography

Recorded positions across the country.

No public positions recorded for this legislation.

Arguments

Reasons offered for and against this legislation.

Arguments in favor

No arguments in favor have been submitted.

Submit yours

Arguments opposed

No arguments opposed have been submitted.

Submit yours

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Progress